# Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 3.6 | nc | (nc-nc) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 1.9 | nc | (nc-nc) |
| Female | 11 | 11.2 | 97.8 | (48.8-175.1) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 3 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 11.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 4 | 2.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 6.4 | 78.2 | (25.2-182.6) |  | Male | 30 | 44.3 | 67.8 | (45.7-96.7) |
| Female | 4 | 5.4 | nc | (nc-nc) |  | Female | 34 | 36.5 | 93.2 | (64.6-130.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

163

# Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 26 | 42.5 | 61.2 | (40.0-89.7) |  | Male | 26 | 26.3 | 98.9 | (64.6-144.9) |
| Female | 3 | 15.4 | nc | (nc-nc) |  | Female | 24 | 20.6 | 116.8 | (74.8-173.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 7.3 | nc | (nc-nc) |  | Male | 12 | 8.5 | 141.3 | (72.9-246.9) |
| Female | 6 | 6.6 | 91.0 | (33.2-198.2) |  | Female | 8 | 7.1 | 112.6 | (48.5-221.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 1.5 | nc | (nc-nc) |  | Male | 19 | 23.2 | 81.8 | (49.2-127.7) |
| Female | 183 | 168.0 | 108.9 | (93.7-125.9) |  | Female | 21 | 20.8 | 101.1 | (62.6-154.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 18 | 18.9 | 95.1 | (56.4-150.4) |
| Female | 1 | 5.3 | nc | (nc-nc) |  | Female | 4 | 9.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 37 | 43.5 | 85.1 | (59.9-117.2) |  |  |  |  |  |  |
| Female | 28 | 44.5 | 62.9 | (41.8-90.9) |  | Female | 15 | 14.4 | 104.4 | (58.4-172.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 10.3 | 48.4 | (15.6-112.8) |  | Male | 16 | 15.4 | 103.9 | (59.4-168.8) |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 18 | 16.3 | 110.5 | (65.4-174.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 129 | 120.5 | 107.0 | (89.3-127.2) |
| Female | 1 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 23.2 | 64.7 | (36.2-106.7) |  | Male | 1 | 9.8 | nc | (nc-nc) |
| Female | 5 | 13.4 | 37.3 | (12.0-87.0) |  | Female | 2 | 6.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 5.9 | nc | (nc-nc) |  | Male | 6 | 4.3 | 139.3 | (50.9-303.1) |
| Female | 0 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 17 | 16.4 | 104.0 | (60.5-166.5) |  | Male | 11 | 9.8 | 112.0 | (55.8-200.4) |
| Female | 10 | 12.3 | 81.5 | (39.0-149.9) |  | Female | 34 | 28.9 | 117.7 | (81.5-164.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 14.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 5.0 | 99.6 | (32.1-232.3) |  | Female | 32 | 37.4 | 85.6 | (58.5-120.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 72.6 | 39.9 | (26.7-57.4) |  | Male | 416 | 518.7 | 80.2 | (72.7-88.3) |
| Female | 40 | 79.5 | 50.3 | (35.9-68.5) |  | Female | 483 | 564.1 | 85.6 | (78.2-93.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

164

# Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 2 | 4.1 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 1 | 3.4 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 9 | 12.5 | 72.2 | (32.9-137.0) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 16 | 12.5 | 127.7 | (73.0-207.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

165

# Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 9.9 | nc | (nc-nc) |  | Male | 7 | 6.0 | 117.6 | (47.1-242.4) |
| Female | 8 | 3.0 | 262.3 | (113.0-516.9) |  | Female | 7 | 4.1 | 171.2 | (68.6-352.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 1.6 | 372.3 | (135.9-810.4) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 5.3 | nc | (nc-nc) |
| Female | 44 | 31.9 | 137.9 | (100.2-185.2) |  | Female | 2 | 4.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 4.0 | 150.9 | (55.1-328.5) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 9.8 | 71.4 | (28.6-147.1) |  |  |  |  |  |  |
| Female | 8 | 8.9 | 89.7 | (38.6-176.7) |  | Female | 4 | 2.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 5 | 3.5 | 143.1 | (46.1-334.0) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 42 | 24.3 | 173.1 | (124.8-234.0) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 4.9 | nc | (nc-nc) |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 3.8 | 186.2 | (74.6-383.7) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 5 | 2.6 | 195.9 | (63.1-457.3) |  | Female | 6 | 5.7 | 105.9 | (38.7-230.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 13 | 7.2 | 179.5 | (95.5-307.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 16.3 | 36.7 | (13.4-80.0) |  | Male | 118 | 114.1 | 103.4 | (85.6-123.8) |
| Female | 9 | 15.1 | 59.6 | (27.2-113.2) |  | Female | 129 | 109.9 | 117.3 | (98.0-139.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

166

# Littleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 9.2 | 142.0 | (75.5-242.9) |  | Male | 6 | 6.4 | 93.6 | (34.2-203.7) |
| Female | 1 | 3.9 | nc | (nc-nc) |  | Female | 4 | 5.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 8 | 5.6 | 142.3 | (61.3-280.3) |
| Female | 49 | 45.1 | 108.6 | (80.4-143.6) |  | Female | 5 | 5.4 | 93.1 | (30.0-217.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 5.1 | 156.3 | (67.3-307.9) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 0 | 2.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 10.3 | 58.0 | (21.2-126.2) |  |  |  |  |  |  |
| Female | 8 | 11.3 | 70.9 | (30.5-139.7) |  | Female | 6 | 3.9 | 155.2 | (56.7-337.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 8 | 3.6 | 221.8 | (95.5-437.1) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 4 | 4.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 0.7 | nc | (nc-nc) |  | Male | 35 | 30.7 | 114.0 | (79.4-158.5) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 6.0 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 4 | 3.6 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 3.9 | 153.3 | (56.0-333.8) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 8 | 8.2 | 97.8 | (42.1-192.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 12 | 10.3 | 116.8 | (60.3-204.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 16.7 | 101.8 | (59.3-163.0) |  | Male | 131 | 126.7 | 103.4 | (86.4-122.7) |
| Female | 14 | 20.8 | 67.4 | (36.8-113.0) |  | Female | 132 | 149.0 | 88.6 | (74.1-105.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

167

# Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 22.0 | 63.7 | (34.8-106.9) |  | Male | 16 | 13.3 | 120.4 | (68.7-195.5) |
| Female | 6 | 7.9 | 75.7 | (27.6-164.7) |  | Female | 12 | 10.2 | 117.3 | (60.6-205.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 5 | 3.3 | 151.1 | (48.7-352.7) |  | Female | 1 | 3.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 11 | 11.7 | 94.4 | (47.1-168.9) |
| Female | 88 | 82.1 | 107.2 | (86.0-132.1) |  | Female | 11 | 10.4 | 105.5 | (52.6-188.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 9.5 | 73.8 | (29.5-152.0) |
| Female | 0 | 2.6 | nc | (nc-nc) |  | Female | 0 | 4.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 22.3 | 62.7 | (34.2-105.2) |  |  |  |  |  |  |
| Female | 13 | 23.2 | 56.0 | (29.8-95.7) |  | Female | 6 | 7.1 | 84.0 | (30.7-182.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 5.2 | nc | (nc-nc) |  | Male | 4 | 7.9 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 5 | 8.5 | 58.7 | (18.9-137.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 50 | 61.0 | 81.9 | (60.8-108.0) |
| Female | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 11.5 | 95.3 | (47.5-170.6) |  | Male | 4 | 5.0 | nc | (nc-nc) |
| Female | 4 | 6.6 | nc | (nc-nc) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  | Male | 3 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 8.2 | 121.5 | (58.2-223.5) |  | Male | 6 | 4.7 | 128.1 | (46.8-278.7) |
| Female | 2 | 6.3 | nc | (nc-nc) |  | Female | 8 | 13.8 | 57.8 | (24.9-114.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 7.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 7 | 2.5 | 278.8 | (111.7-574.5) |  | Female | 13 | 18.0 | 72.1 | (38.4-123.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 26 | 37.1 | 70.1 | (45.8-102.7) |  | Male | 214 | 262.6 | 81.5 | (70.9-93.2) |
| Female | 23 | 39.6 | 58.0 | (36.8-87.0) |  | Female | 236 | 281.4 | 83.9 | (73.5-95.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

168

# Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 81 | 82.9 | 97.7 | (77.6-121.5) |  | Male | 25 | 57.6 | 43.4 | (28.1-64.0) |
| Female | 35 | 32.1 | 108.9 | (75.8-151.4) |  | Female | 28 | 48.8 | 57.4 | (38.1-82.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 13 | 19.5 | 66.8 | (35.5-114.2) |  | Male | 19 | 18.0 | 105.3 | (63.4-164.5) |
| Female | 12 | 16.6 | 72.1 | (37.2-126.0) |  | Female | 19 | 15.1 | 126.1 | (75.9-196.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 34 | 51.6 | 65.9 | (45.6-92.1) |
| Female | 329 | 378.4 | 86.9 | (77.8-96.9) |  | Female | 36 | 45.5 | 79.1 | (55.4-109.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 59 | 45.3 | 130.2 | (99.1-167.9) |
| Female | 20 | 13.4 | 149.5 | (91.3-230.8) |  | Female | 11 | 20.4 | 54.0 | (26.9-96.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 92 | 93.9 | 98.0 | (79.0-120.1) |  |  |  |  |  |  |
| Female | 107 | 94.3 | 113.5 | (93.0-137.1) |  | Female | 32 | 32.9 | 97.3 | (66.5-137.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 20 | 22.3 | 89.8 | (54.8-138.7) |  | Male | 30 | 32.0 | 93.7 | (63.2-133.7) |
| Female | 6 | 6.3 | 95.7 | (35.0-208.4) |  | Female | 33 | 33.4 | 98.9 | (68.1-138.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 14 | 9.0 | 156.1 | (85.3-262.0) |  | Male | 206 | 270.1 | 76.3 | (66.2-87.4) |
| Female | 5 | 7.7 | 65.0 | (21.0-151.8) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 67 | 54.1 | 123.9 | (96.0-157.3) |  | Male | 23 | 20.4 | 112.8 | (71.5-169.2) |
| Female | 30 | 30.1 | 99.7 | (67.3-142.4) |  | Female | 33 | 13.3 | 249.0 | (171.4-349.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 15 | 13.1 | 114.8 | (64.2-189.3) |  | Male | 14 | 18.0 | 77.9 | (42.5-130.7) |
| Female | 7 | 4.1 | 171.3 | (68.6-353.0) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 36 | 37.6 | 95.8 | (67.1-132.7) |  | Male | 20 | 27.3 | 73.3 | (44.7-113.1) |
| Female | 32 | 28.2 | 113.5 | (77.6-160.2) |  | Female | 88 | 79.4 | 110.8 | (88.9-136.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 60 | 32.4 | 185.4 | (141.5-238.7) |  |  |  |  |  |  |
| Female | 15 | 11.0 | 136.4 | (76.3-225.0) |  | Female | 69 | 84.4 | 81.8 | (63.6-103.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 175 | 147.1 | 119.0 | (102.0-138.0) |  | Male | 1110 | 1144.8 | 97.0 | (91.3-102.8) |
| Female | 188 | 168.9 | 111.3 | (96.0-128.4) |  | Female | 1234 | 1263.9 | 97.6 | (92.3-103.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

169

# Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 28 | 26.7 | 105.0 | (69.8-151.8) |  | Male | 11 | 17.0 | 64.6 | (32.2-115.6) |
| Female | 5 | 10.3 | 48.4 | (15.6-112.9) |  | Female | 13 | 13.3 | 97.7 | (52.0-167.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 4.9 | nc | (nc-nc) |  | Male | 4 | 5.5 | nc | (nc-nc) |
| Female | 2 | 4.2 | nc | (nc-nc) |  | Female | 7 | 4.7 | 148.5 | (59.5-306.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 15 | 15.0 | 99.7 | (55.8-164.5) |
| Female | 99 | 107.7 | 92.0 | (74.7-112.0) |  | Female | 16 | 13.7 | 116.6 | (66.6-189.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 12.8 | 47.0 | (17.2-102.3) |
| Female | 6 | 3.3 | 182.8 | (66.7-397.9) |  | Female | 4 | 6.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 27 | 27.7 | 97.5 | (64.2-141.8) |  |  |  |  |  |  |
| Female | 30 | 29.0 | 103.5 | (69.8-147.8) |  | Female | 8 | 9.4 | 85.5 | (36.8-168.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 6.8 | nc | (nc-nc) |  | Male | 10 | 9.9 | 101.1 | (48.4-186.0) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 10 | 10.8 | 92.6 | (44.3-170.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 50 | 81.2 | 61.5 | (45.7-81.1) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 22 | 15.3 | 143.7 | (90.0-217.6) |  | Male | 8 | 6.3 | 127.9 | (55.1-252.0) |
| Female | 5 | 8.8 | 57.0 | (18.4-133.0) |  | Female | 5 | 4.1 | 121.6 | (39.2-283.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 3.9 | 126.8 | (40.9-296.0) |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 10.5 | 57.0 | (20.8-124.0) |  | Male | 4 | 6.7 | nc | (nc-nc) |
| Female | 7 | 8.0 | 87.2 | (34.9-179.6) |  | Female | 8 | 18.1 | 44.3 | (19.1-87.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 9.6 | 103.7 | (49.6-190.7) |  |  |  |  |  |  |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 27 | 24.6 | 109.8 | (72.3-159.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 35 | 46.7 | 74.9 | (52.2-104.2) |  | Male | 282 | 339.4 | 83.1 | (73.7-93.4) |
| Female | 32 | 53.4 | 59.9 | (41.0-84.6) |  | Female | 318 | 367.8 | 86.5 | (77.2-96.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

170

# Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 12.7 | 86.5 | (43.1-154.7) |  | Male | 10 | 8.1 | 122.9 | (58.8-226.0) |
| Female | 7 | 4.5 | 154.9 | (62.1-319.3) |  | Female | 2 | 6.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 2.3 | nc | (nc-nc) |  | Male | 5 | 2.6 | 192.5 | (62.0-449.1) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 6 | 7.2 | 83.1 | (30.3-180.9) |
| Female | 64 | 54.9 | 116.6 | (89.8-148.9) |  | Female | 6 | 6.5 | 92.8 | (33.9-202.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.1 | 98.1 | (35.8-213.5) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 0 | 2.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 13.7 | 72.8 | (34.8-133.8) |  |  |  |  |  |  |
| Female | 15 | 13.1 | 114.6 | (64.1-189.0) |  | Female | 2 | 4.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 2 | 4.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 0.8 | nc | (nc-nc) |  | Male | 35 | 37.5 | 93.3 | (65.0-129.8) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 7.4 | 94.8 | (38.0-195.4) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 3 | 4.2 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 1.8 | nc | (nc-nc) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 5.0 | 158.7 | (68.3-312.7) |  | Male | 5 | 3.3 | 150.8 | (48.6-351.9) |
| Female | 6 | 3.7 | 163.7 | (59.8-356.3) |  | Female | 12 | 10.0 | 120.3 | (62.1-210.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 4.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 16 | 12.7 | 126.1 | (72.0-204.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 23 | 21.6 | 106.5 | (67.5-159.8) |  | Male | 165 | 160.6 | 102.8 | (87.7-119.7) |
| Female | 18 | 23.8 | 75.6 | (44.8-119.4) |  | Female | 171 | 177.6 | 96.3 | (82.4-111.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

171

# Lynn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 84 | 72.8 | 115.4 | (92.0-142.8) |  | Male | 41 | 49.5 | 82.8 | (59.4-112.4) |
| Female | 26 | 27.6 | 94.2 | (61.5-138.0) |  | Female | 37 | 42.2 | 87.7 | (61.7-120.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 19 | 16.3 | 116.5 | (70.1-182.0) |  | Male | 31 | 15.6 | 199.2 | (135.3-282.8) |
| Female | 20 | 14.4 | 139.0 | (84.9-214.7) |  | Female | 18 | 13.1 | 137.7 | (81.6-217.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 5 | 2.6 | 189.1 | (60.9-441.3) |  | Male | 49 | 44.2 | 110.8 | (82.0-146.5) |
| Female | 307 | 329.9 | 93.1 | (82.9-104.1) |  | Female | 49 | 39.4 | 124.4 | (92.1-164.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 44 | 37.8 | 116.5 | (84.6-156.4) |
| Female | 16 | 11.6 | 138.0 | (78.9-224.2) |  | Female | 24 | 17.6 | 136.0 | (87.1-202.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 117 | 80.9 | 144.6 | (119.6-173.3) |  |  |  |  |  |  |
| Female | 112 | 81.3 | 137.8 | (113.5-165.9) |  | Female | 25 | 28.5 | 87.6 | (56.7-129.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 15 | 19.0 | 79.0 | (44.2-130.4) |  | Male | 35 | 27.7 | 126.5 | (88.1-175.9) |
| Female | 4 | 5.4 | nc | (nc-nc) |  | Female | 25 | 28.7 | 87.0 | (56.3-128.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 7.2 | 83.0 | (30.3-180.7) |  | Male | 284 | 225.3 | 126.1 | (111.8-141.6) |
| Female | 3 | 6.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 40 | 45.6 | 87.7 | (62.6-119.4) |  | Male | 20 | 17.7 | 113.3 | (69.2-175.0) |
| Female | 29 | 26.1 | 111.0 | (74.3-159.4) |  | Female | 16 | 11.4 | 140.1 | (80.0-227.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 12 | 11.1 | 107.8 | (55.7-188.4) |  | Male | 11 | 14.7 | 74.6 | (37.2-133.5) |
| Female | 5 | 3.6 | 140.5 | (45.3-327.8) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 44 | 32.1 | 137.2 | (99.7-184.2) |  | Male | 20 | 22.6 | 88.4 | (53.9-136.5) |
| Female | 29 | 24.5 | 118.4 | (79.3-170.0) |  | Female | 61 | 68.4 | 89.2 | (68.3-114.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 53 | 27.0 | 196.5 | (147.2-257.0) |  |  |  |  |  |  |
| Female | 21 | 9.5 | 221.0 | (136.7-337.8) |  | Female | 80 | 73.7 | 108.5 | (86.0-135.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 197 | 128.0 | 153.9 | (133.2-177.0) |  | Male | 1209 | 975.5 | 123.9 | (117.0-131.1) |
| Female | 179 | 145.4 | 123.1 | (105.7-142.5) |  | Female | 1190 | 1095.0 | 108.7 | (102.6-115.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

172

# Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 18.3 | 70.9 | (37.7-121.2) |  | Male | 26 | 11.1 | 233.8 | (152.7-342.6) |
| Female | 6 | 5.4 | 110.4 | (40.3-240.4) |  | Female | 12 | 7.4 | 161.6 | (83.4-282.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 5 | 2.4 | 210.9 | (68.0-492.3) |  | Female | 5 | 2.5 | 196.6 | (63.4-458.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 13 | 9.8 | 132.6 | (70.6-226.8) |
| Female | 67 | 61.4 | 109.2 | (84.6-138.7) |  | Female | 14 | 7.4 | 189.5 | (103.5-318.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 7.9 | 63.3 | (20.4-147.8) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 18.6 | 64.5 | (33.3-112.6) |  |  |  |  |  |  |
| Female | 21 | 15.5 | 135.4 | (83.8-206.9) |  | Female | 8 | 5.2 | 153.0 | (65.9-301.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 4.4 | nc | (nc-nc) |  | Male | 4 | 6.6 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 5 | 5.7 | 87.9 | (28.3-205.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 40 | 50.4 | 79.3 | (56.7-108.0) |
| Female | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 9.6 | 83.1 | (35.8-163.7) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 5 | 4.9 | 102.4 | (33.0-239.0) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 7 | 1.7 | 403.6 | (161.7-831.6) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 6.9 | 174.5 | (90.1-304.8) |  | Male | 7 | 4.0 | 175.5 | (70.3-361.7) |
| Female | 3 | 4.3 | nc | (nc-nc) |  | Female | 17 | 10.7 | 158.5 | (92.3-253.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 15 | 13.9 | 107.5 | (60.1-177.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 31.0 | 45.2 | (24.7-75.9) |  | Male | 190 | 219.1 | 86.7 | (74.8-99.9) |
| Female | 25 | 28.7 | 87.1 | (56.3-128.5) |  | Female | 226 | 203.5 | 111.0 | (97.0-126.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

173

# Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 30 | 48.4 | 61.9 | (41.8-88.4) |  | Male | 10 | 33.4 | 30.0 | (14.4-55.1) |
| Female | 19 | 19.2 | 99.0 | (59.6-154.7) |  | Female | 12 | 29.1 | 41.3 | (21.3-72.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 10.8 | 46.1 | (14.9-107.6) |  | Male | 10 | 10.4 | 95.8 | (45.9-176.2) |
| Female | 8 | 9.7 | 82.8 | (35.7-163.2) |  | Female | 4 | 9.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 47 | 29.8 | 157.5 | (115.7-209.5) |
| Female | 200 | 222.5 | 89.9 | (77.9-103.2) |  | Female | 23 | 27.1 | 84.7 | (53.7-127.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 29 | 25.2 | 115.1 | (77.1-165.4) |
| Female | 15 | 8.0 | 188.5 | (105.4-310.9) |  | Female | 14 | 12.1 | 115.8 | (63.3-194.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 65 | 53.1 | 122.4 | (94.4-156.0) |  |  |  |  |  |  |
| Female | 67 | 56.2 | 119.1 | (92.3-151.3) |  | Female | 16 | 19.4 | 82.6 | (47.2-134.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 21 | 12.8 | 164.4 | (101.7-251.2) |  | Male | 19 | 18.5 | 102.8 | (61.9-160.5) |
| Female | 8 | 3.7 | 214.1 | (92.2-422.0) |  | Female | 20 | 20.0 | 99.8 | (60.9-154.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 5.2 | nc | (nc-nc) |  | Male | 144 | 152.2 | 94.6 | (79.8-111.4) |
| Female | 5 | 4.7 | 107.5 | (34.6-250.8) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 32 | 30.5 | 104.9 | (71.7-148.1) |  | Male | 20 | 11.8 | 169.9 | (103.8-262.5) |
| Female | 20 | 17.7 | 112.8 | (68.9-174.2) |  | Female | 12 | 7.9 | 151.7 | (78.3-265.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 7.5 | 66.3 | (21.4-154.8) |  | Male | 6 | 10.8 | 55.8 | (20.4-121.4) |
| Female | 2 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 21.3 | 84.6 | (50.1-133.8) |  | Male | 13 | 15.6 | 83.2 | (44.3-142.3) |
| Female | 16 | 16.6 | 96.3 | (55.0-156.4) |  | Female | 56 | 47.1 | 119.0 | (89.9-154.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 29 | 18.4 | 157.7 | (105.6-226.6) |  |  |  |  |  |  |
| Female | 16 | 6.5 | 244.8 | (139.8-397.5) |  | Female | 41 | 49.8 | 82.4 | (59.1-111.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 114 | 86.3 | 132.1 | (109.0-158.7) |  | Male | 655 | 655.5 | 99.9 | (92.4-107.9) |
| Female | 99 | 100.1 | 98.9 | (80.4-120.4) |  | Female | 728 | 748.3 | 97.3 | (90.3-104.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

174

# Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 9.3 | nc | (nc-nc) |  | Male | 8 | 5.4 | 146.9 | (63.2-289.5) |
| Female | 1 | 2.8 | nc | (nc-nc) |  | Female | 5 | 3.7 | 136.6 | (44.0-318.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 6 | 4.8 | 125.4 | (45.8-273.0) |
| Female | 32 | 31.1 | 102.9 | (70.4-145.3) |  | Female | 2 | 3.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 9.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 9 | 7.7 | 117.3 | (53.5-222.6) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 5 | 2.9 | 172.7 | (55.6-402.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 23 | 25.7 | 89.6 | (56.8-134.5) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 4.7 | nc | (nc-nc) |  | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 7 | 5.0 | 138.8 | (55.6-286.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 4 | 7.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 15.9 | 44.2 | (17.7-91.0) |  | Male | 80 | 108.8 | 73.5 | (58.3-91.5) |
| Female | 8 | 15.0 | 53.4 | (23.0-105.1) |  | Female | 89 | 102.8 | 86.5 | (69.5-106.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

175

# Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 17.3 | 132.7 | (84.1-199.2) |  | Male | 20 | 12.5 | 160.4 | (97.9-247.8) |
| Female | 1 | 5.9 | nc | (nc-nc) |  | Female | 20 | 10.7 | 187.1 | (114.2-288.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 4.2 | 192.5 | (82.9-379.3) |  | Male | 5 | 3.9 | 128.4 | (41.4-299.8) |
| Female | 6 | 3.5 | 170.7 | (62.3-371.6) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 14 | 11.2 | 125.5 | (68.5-210.5) |
| Female | 99 | 87.5 | 113.1 | (91.9-137.7) |  | Female | 3 | 9.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 10.1 | 69.4 | (27.8-142.9) |
| Female | 0 | 3.3 | nc | (nc-nc) |  | Female | 3 | 4.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 20.6 | 116.6 | (74.7-173.5) |  |  |  |  |  |  |
| Female | 27 | 19.1 | 141.6 | (93.3-206.1) |  | Female | 10 | 7.2 | 138.0 | (66.1-253.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 4.8 | nc | (nc-nc) |  | Male | 5 | 6.9 | 72.8 | (23.5-169.9) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 4 | 6.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 62 | 58.7 | 105.5 | (80.9-135.3) |
| Female | 2 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 12.1 | 91.1 | (45.4-163.1) |  | Male | 2 | 4.4 | nc | (nc-nc) |
| Female | 4 | 6.4 | nc | (nc-nc) |  | Female | 4 | 2.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.8 | nc | (nc-nc) |  | Male | 8 | 3.7 | 216.9 | (93.4-427.4) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 7.9 | 101.1 | (43.5-199.2) |  | Male | 13 | 6.2 | 208.9 | (111.1-357.2) |
| Female | 8 | 5.6 | 143.8 | (61.9-283.4) |  | Female | 15 | 19.5 | 77.1 | (43.1-127.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 7.0 | 142.2 | (68.1-261.6) |  |  |  |  |  |  |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 12 | 18.7 | 64.1 | (33.1-112.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 37 | 30.9 | 119.6 | (84.2-164.8) |  | Male | 276 | 246.5 | 112.0 | (99.1-126.0) |
| Female | 28 | 32.3 | 86.6 | (57.6-125.2) |  | Female | 279 | 269.9 | 103.4 | (91.6-116.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

176

# Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 25 | 30.1 | 83.1 | (53.8-122.7) |  | Male | 41 | 18.3 | 224.0 | (160.7-303.9) |
| Female | 7 | 10.4 | 67.4 | (27.0-138.9) |  | Female | 24 | 13.8 | 174.2 | (111.5-259.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 5.0 | nc | (nc-nc) |  | Male | 7 | 6.0 | 116.6 | (46.7-240.3) |
| Female | 4 | 4.4 | nc | (nc-nc) |  | Female | 8 | 4.8 | 166.0 | (71.5-327.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 14 | 16.1 | 87.0 | (47.5-145.9) |
| Female | 113 | 115.7 | 97.7 | (80.5-117.5) |  | Female | 15 | 14.0 | 107.2 | (59.9-176.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 13.0 | 92.0 | (47.5-160.8) |
| Female | 4 | 3.5 | nc | (nc-nc) |  | Female | 5 | 6.2 | 80.1 | (25.8-186.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 23 | 29.8 | 77.2 | (48.9-115.8) |  |  |  |  |  |  |
| Female | 22 | 29.1 | 75.6 | (47.3-114.4) |  | Female | 5 | 9.8 | 50.9 | (16.4-118.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 7.3 | 122.7 | (56.0-233.0) |  | Male | 8 | 10.8 | 73.7 | (31.8-145.3) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 15 | 10.8 | 138.9 | (77.7-229.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 84 | 85.6 | 98.1 | (78.2-121.5) |
| Female | 4 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 16.0 | 74.9 | (38.6-130.8) |  | Male | 6 | 6.8 | 87.6 | (32.0-190.7) |
| Female | 7 | 9.2 | 75.9 | (30.4-156.3) |  | Female | 1 | 4.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 4.2 | nc | (nc-nc) |  | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 11.3 | 105.9 | (54.7-185.1) |  | Male | 7 | 6.3 | 110.9 | (44.4-228.5) |
| Female | 9 | 8.0 | 112.4 | (51.3-213.3) |  | Female | 17 | 19.4 | 87.6 | (51.0-140.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 10.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 3.4 | nc | (nc-nc) |  | Female | 22 | 26.4 | 83.3 | (52.2-126.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 52.4 | 53.4 | (35.5-77.2) |  | Male | 323 | 363.4 | 88.9 | (79.5-99.1) |
| Female | 39 | 55.4 | 70.4 | (50.1-96.3) |  | Female | 357 | 383.5 | 93.1 | (83.7-103.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

177

# Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 7.9 | 89.0 | (35.7-183.4) |  | Male | 11 | 4.7 | 235.4 | (117.4-421.3) |
| Female | 5 | 3.0 | 167.3 | (53.9-390.3) |  | Female | 2 | 3.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 10 | 4.2 | 239.8 | (114.8-441.0) |
| Female | 31 | 29.3 | 105.6 | (71.8-150.0) |  | Female | 3 | 3.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 7.6 | 144.3 | (72.0-258.3) |  |  |  |  |  |  |
| Female | 10 | 8.3 | 120.5 | (57.7-221.7) |  | Female | 0 | 2.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 14 | 22.9 | 61.2 | (33.5-102.8) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 4.1 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 2.9 | 206.7 | (75.5-449.9) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 4 | 2.3 | nc | (nc-nc) |  | Female | 6 | 4.5 | 134.4 | (49.1-292.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 7 | 6.7 | 104.4 | (41.8-215.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 13.6 | 73.4 | (35.1-134.9) |  | Male | 99 | 94.4 | 104.9 | (85.2-127.7) |
| Female | 16 | 15.1 | 106.1 | (60.6-172.3) |  | Female | 108 | 101.9 | 106.0 | (86.9-128.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

178

# Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 36 | 39.6 | 90.8 | (63.6-125.8) |  | Male | 26 | 26.5 | 98.3 | (64.2-144.0) |
| Female | 12 | 13.4 | 89.6 | (46.3-156.6) |  | Female | 13 | 19.8 | 65.6 | (34.9-112.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 8.1 | 86.0 | (34.5-177.2) |  | Male | 9 | 8.4 | 107.7 | (49.2-204.5) |
| Female | 10 | 6.5 | 154.3 | (73.9-283.7) |  | Female | 7 | 6.3 | 110.9 | (44.4-228.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 16 | 23.3 | 68.6 | (39.2-111.3) |
| Female | 152 | 158.0 | 96.2 | (81.5-112.8) |  | Female | 26 | 18.9 | 137.5 | (89.8-201.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 19 | 19.9 | 95.4 | (57.4-149.0) |
| Female | 9 | 5.5 | 163.3 | (74.5-310.1) |  | Female | 20 | 8.4 | 237.6 | (145.1-367.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 43 | 43.0 | 100.0 | (72.3-134.7) |  |  |  |  |  |  |
| Female | 44 | 38.6 | 114.0 | (82.8-153.0) |  | Female | 16 | 13.5 | 118.3 | (67.6-192.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 10.2 | 97.8 | (46.8-179.9) |  | Male | 14 | 14.9 | 94.0 | (51.3-157.7) |
| Female | 5 | 2.6 | 190.5 | (61.4-444.5) |  | Female | 15 | 13.8 | 108.3 | (60.6-178.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 7 | 3.4 | 208.2 | (83.4-428.9) |  | Male | 102 | 120.6 | 84.6 | (69.0-102.7) |
| Female | 3 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 24.1 | 62.2 | (34.8-102.7) |  | Male | 4 | 9.5 | nc | (nc-nc) |
| Female | 13 | 12.5 | 103.9 | (55.3-177.7) |  | Female | 7 | 5.4 | 129.9 | (52.0-267.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 6.0 | 100.3 | (36.6-218.2) |  | Male | 3 | 6.8 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 16.6 | 72.1 | (37.2-125.9) |  | Male | 13 | 11.5 | 113.2 | (60.2-193.6) |
| Female | 14 | 11.2 | 125.0 | (68.3-209.7) |  | Female | 38 | 31.4 | 120.9 | (85.5-165.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 14 | 14.5 | 96.3 | (52.6-161.6) |  |  |  |  |  |  |
| Female | 7 | 4.6 | 152.7 | (61.2-314.6) |  | Female | 36 | 35.8 | 100.6 | (70.4-139.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 56 | 70.0 | 80.0 | (60.4-103.9) |  | Male | 445 | 519.6 | 85.6 | (77.9-94.0) |
| Female | 76 | 71.3 | 106.6 | (84.0-133.5) |  | Female | 569 | 522.5 | 108.9 | (100.1-118.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

179

# Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 24 | 29.0 | 82.8 | (53.0-123.2) |  | Male | 31 | 19.1 | 162.4 | (110.3-230.5) |
| Female | 10 | 9.7 | 103.1 | (49.4-189.7) |  | Female | 29 | 14.4 | 201.1 | (134.6-288.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 11 | 5.6 | 196.6 | (98.0-351.8) |  | Male | 10 | 6.2 | 162.1 | (77.6-298.1) |
| Female | 4 | 4.7 | nc | (nc-nc) |  | Female | 4 | 4.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 10 | 16.8 | 59.5 | (28.5-109.5) |
| Female | 145 | 121.4 | 119.5 | (100.8-140.6) |  | Female | 13 | 13.9 | 93.4 | (49.7-159.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 15.0 | 113.2 | (65.9-181.3) |
| Female | 4 | 3.9 | nc | (nc-nc) |  | Female | 5 | 6.3 | 78.9 | (25.4-184.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 23 | 31.3 | 73.4 | (46.5-110.2) |  |  |  |  |  |  |
| Female | 27 | 27.6 | 97.9 | (64.5-142.4) |  | Female | 8 | 10.2 | 78.7 | (33.9-155.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 7.7 | 91.0 | (36.5-187.6) |  | Male | 12 | 11.1 | 108.5 | (56.0-189.6) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 10 | 10.0 | 100.5 | (48.1-184.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 102 | 95.1 | 107.2 | (87.4-130.2) |
| Female | 3 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 20 | 17.9 | 111.6 | (68.2-172.4) |  | Male | 5 | 7.0 | 71.8 | (23.1-167.6) |
| Female | 6 | 9.4 | 63.9 | (23.3-139.2) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 4.5 | nc | (nc-nc) |  | Male | 5 | 3.6 | 140.6 | (45.3-328.2) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 11.8 | 127.5 | (71.3-210.2) |  | Male | 8 | 7.8 | 102.4 | (44.1-201.8) |
| Female | 5 | 7.9 | 63.4 | (20.4-147.9) |  | Female | 17 | 22.4 | 75.9 | (44.2-121.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 11.0 | 118.5 | (63.0-202.7) |  |  |  |  |  |  |
| Female | 0 | 3.4 | nc | (nc-nc) |  | Female | 21 | 28.3 | 74.3 | (46.0-113.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 49 | 51.9 | 94.4 | (69.8-124.8) |  | Male | 392 | 384.5 | 102.0 | (92.1-112.6) |
| Female | 71 | 53.3 | 133.3 | (104.1-168.1) |  | Female | 414 | 389.2 | 106.4 | (96.4-117.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

180

# Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 25 | 24.6 | 101.7 | (65.8-150.2) |  | Male | 17 | 14.4 | 118.4 | (68.9-189.5) |
| Female | 6 | 8.8 | 68.5 | (25.0-149.1) |  | Female | 16 | 10.5 | 152.9 | (87.4-248.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.8 | nc | (nc-nc) |  | Male | 10 | 4.8 | 209.5 | (100.3-385.3) |
| Female | 1 | 3.4 | nc | (nc-nc) |  | Female | 2 | 4.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 18 | 12.6 | 143.0 | (84.7-226.0) |
| Female | 96 | 89.4 | 107.3 | (86.9-131.1) |  | Female | 10 | 11.4 | 88.0 | (42.1-161.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 9.8 | 143.4 | (78.3-240.6) |
| Female | 0 | 2.4 | nc | (nc-nc) |  | Female | 5 | 5.0 | 101.0 | (32.5-235.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 23.1 | 69.2 | (39.5-112.4) |  |  |  |  |  |  |
| Female | 19 | 23.2 | 81.7 | (49.2-127.7) |  | Female | 4 | 7.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 5.8 | 85.5 | (27.6-199.6) |  | Male | 10 | 8.6 | 115.9 | (55.5-213.1) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 8 | 9.0 | 89.2 | (38.4-175.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 60 | 67.7 | 88.7 | (67.7-114.1) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 12.2 | 57.2 | (22.9-117.8) |  | Male | 4 | 5.5 | nc | (nc-nc) |
| Female | 7 | 7.4 | 94.3 | (37.8-194.2) |  | Female | 1 | 3.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.4 | nc | (nc-nc) |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 8.9 | 90.3 | (38.9-177.9) |  | Male | 3 | 4.5 | nc | (nc-nc) |
| Female | 11 | 6.4 | 171.6 | (85.6-307.1) |  | Female | 7 | 13.1 | 53.4 | (21.4-109.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 7.7 | 65.3 | (21.0-152.4) |  |  |  |  |  |  |
| Female | 1 | 2.8 | nc | (nc-nc) |  | Female | 18 | 20.9 | 86.0 | (50.9-135.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 40 | 43.0 | 93.1 | (66.5-126.8) |  | Male | 275 | 286.8 | 95.9 | (84.9-107.9) |
| Female | 57 | 47.6 | 119.9 | (90.8-155.3) |  | Female | 302 | 304.4 | 99.2 | (88.3-111.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

181

# Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 8.4 | 142.4 | (73.5-248.8) |  | Male | 4 | 5.3 | nc | (nc-nc) |
| Female | 3 | 2.9 | nc | (nc-nc) |  | Female | 2 | 3.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 1 | 4.6 | nc | (nc-nc) |
| Female | 37 | 33.5 | 110.5 | (77.8-152.3) |  | Female | 4 | 4.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 4.0 | 328.8 | (174.9-562.4) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 8.6 | 151.7 | (80.7-259.5) |  |  |  |  |  |  |
| Female | 3 | 8.0 | nc | (nc-nc) |  | Female | 3 | 2.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 35 | 26.6 | 131.5 | (91.6-182.9) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 4.9 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 0 | 2.7 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.3 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 4 | 2.2 | nc | (nc-nc) |  | Female | 5 | 5.6 | 89.9 | (29.0-209.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.0 | nc | (nc-nc) |  | Female | 9 | 7.8 | 115.3 | (52.6-219.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 15.0 | 99.7 | (55.8-164.5) |  | Male | 123 | 106.9 | 115.0 | (95.6-137.2) |
| Female | 14 | 16.1 | 86.9 | (47.5-145.8) |  | Female | 99 | 109.8 | 90.2 | (73.3-109.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

182

# Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 13.8 | 65.4 | (29.9-124.2) |  | Male | 10 | 8.8 | 113.9 | (54.6-209.6) |
| Female | 4 | 3.6 | nc | (nc-nc) |  | Female | 5 | 5.5 | 91.0 | (29.3-212.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 0 | 2.8 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 3 | 7.8 | nc | (nc-nc) |
| Female | 37 | 43.8 | 84.6 | (59.5-116.6) |  | Female | 3 | 5.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.4 | 94.1 | (34.3-204.7) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 14.1 | 120.7 | (70.3-193.3) |  |  |  |  |  |  |
| Female | 15 | 10.5 | 142.6 | (79.7-235.2) |  | Female | 3 | 3.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 4 | 5.1 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 5 | 3.7 | 133.9 | (43.2-312.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 22 | 40.3 | 54.6 | (34.2-82.6) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 7.7 | nc | (nc-nc) |  | Male | 1 | 3.2 | nc | (nc-nc) |
| Female | 4 | 3.5 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 5.5 | nc | (nc-nc) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 6 | 3.0 | 199.0 | (72.7-433.2) |  | Female | 9 | 8.5 | 105.8 | (48.3-200.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 5 | 10.4 | 48.0 | (15.5-112.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 12 | 24.2 | 49.6 | (25.6-86.6) |  | Male | 109 | 172.8 | 63.1 | (51.8-76.1) |
| Female | 20 | 19.2 | 104.2 | (63.6-161.0) |  | Female | 139 | 143.7 | 96.8 | (81.3-114.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

183

# Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 12.8 | 62.6 | (26.9-123.3) |  | Male | 14 | 8.7 | 161.1 | (88.0-270.3) |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 5 | 6.3 | 79.6 | (25.7-185.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 2.6 | 232.7 | (85.0-506.6) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 4 | 1.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 5 | 7.7 | 65.0 | (20.9-151.7) |
| Female | 39 | 53.6 | 72.8 | (51.8-99.5) |  | Female | 4 | 5.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.7 | 88.9 | (32.5-193.5) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 14.3 | 111.8 | (63.9-181.6) |  |  |  |  |  |  |
| Female | 10 | 12.0 | 83.6 | (40.0-153.8) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.4 | nc | (nc-nc) |  | Male | 4 | 5.0 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 3.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 53 | 40.0 | 132.5 | (99.3-173.3) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 8.1 | 86.9 | (34.8-179.1) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 3 | 4.0 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 5.3 | nc | (nc-nc) |  | Male | 3 | 3.8 | nc | (nc-nc) |
| Female | 3 | 3.3 | nc | (nc-nc) |  | Female | 6 | 10.7 | 56.2 | (20.5-122.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 4.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 10 | 11.7 | 85.6 | (41.0-157.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 22.7 | 48.5 | (24.2-86.9) |  | Male | 155 | 170.3 | 91.0 | (77.3-106.5) |
| Female | 14 | 20.7 | 67.5 | (36.9-113.3) |  | Female | 123 | 165.6 | 74.3 | (61.7-88.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

184

# Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 56 | 57.1 | 98.0 | (74.0-127.3) |  | Male | 17 | 36.0 | 47.3 | (27.5-75.7) |
| Female | 22 | 21.9 | 100.4 | (62.9-152.0) |  | Female | 17 | 30.6 | 55.6 | (32.4-89.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 10.9 | 109.8 | (56.7-191.8) |  | Male | 11 | 11.4 | 96.8 | (48.3-173.3) |
| Female | 10 | 10.1 | 98.8 | (47.3-181.8) |  | Female | 9 | 10.1 | 89.1 | (40.6-169.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 30 | 32.0 | 93.7 | (63.2-133.8) |
| Female | 233 | 234.0 | 99.6 | (87.2-113.2) |  | Female | 29 | 29.9 | 96.9 | (64.9-139.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 24 | 25.3 | 94.9 | (60.8-141.2) |
| Female | 6 | 7.8 | 77.4 | (28.3-168.4) |  | Female | 13 | 13.1 | 99.4 | (52.9-170.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 62 | 58.6 | 105.8 | (81.1-135.7) |  |  |  |  |  |  |
| Female | 70 | 61.7 | 113.4 | (88.4-143.3) |  | Female | 19 | 20.7 | 91.7 | (55.2-143.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 14 | 13.8 | 101.6 | (55.5-170.4) |  | Male | 17 | 20.6 | 82.6 | (48.1-132.3) |
| Female | 8 | 4.2 | 189.5 | (81.6-373.4) |  | Female | 22 | 22.7 | 96.8 | (60.7-146.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 4.8 | 104.6 | (33.7-244.2) |  | Male | 148 | 159.3 | 92.9 | (78.6-109.2) |
| Female | 5 | 4.7 | 107.3 | (34.6-250.4) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 28 | 31.1 | 89.9 | (59.8-130.0) |  | Male | 13 | 13.1 | 98.9 | (52.6-169.1) |
| Female | 21 | 19.2 | 109.6 | (67.8-167.5) |  | Female | 9 | 8.7 | 103.0 | (47.0-195.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 8.0 | 87.6 | (35.1-180.5) |  | Male | 10 | 9.4 | 106.8 | (51.1-196.5) |
| Female | 3 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 30 | 23.1 | 130.0 | (87.7-185.6) |  | Male | 13 | 14.3 | 91.0 | (48.4-155.7) |
| Female | 23 | 18.0 | 127.9 | (81.1-192.0) |  | Female | 44 | 45.6 | 96.4 | (70.0-129.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 27 | 18.9 | 142.7 | (94.0-207.6) |  |  |  |  |  |  |
| Female | 6 | 7.3 | 82.1 | (30.0-178.8) |  | Female | 55 | 53.5 | 102.8 | (77.5-133.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 105 | 98.4 | 106.8 | (87.3-129.2) |  | Male | 685 | 706.1 | 97.0 | (89.9-104.6) |
| Female | 142 | 113.9 | 124.7 | (105.0-147.0) |  | Female | 834 | 805.9 | 103.5 | (96.6-110.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

185

# Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 11.2 | 98.2 | (49.0-175.8) |  | Male | 9 | 7.8 | 116.0 | (52.9-220.2) |
| Female | 3 | 4.6 | nc | (nc-nc) |  | Female | 5 | 7.1 | 70.6 | (22.8-164.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.5 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 11 | 6.9 | 158.8 | (79.1-284.1) |
| Female | 63 | 56.9 | 110.7 | (85.1-141.7) |  | Female | 10 | 6.6 | 151.4 | (72.5-278.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 6.3 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 13.1 | 122.1 | (69.7-198.3) |  |  |  |  |  |  |
| Female | 10 | 14.4 | 69.7 | (33.4-128.1) |  | Female | 7 | 4.8 | 145.5 | (58.3-299.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.1 | nc | (nc-nc) |  | Male | 5 | 4.4 | 114.6 | (36.9-267.5) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 2 | 4.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 55 | 37.2 | 148.0 | (111.5-192.7) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 7.5 | 93.6 | (37.5-192.9) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 5 | 4.4 | 114.9 | (37.0-268.2) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 4.8 | nc | (nc-nc) |  | Male | 6 | 3.5 | 169.8 | (62.0-369.5) |
| Female | 6 | 4.0 | 150.7 | (55.0-327.9) |  | Female | 10 | 11.3 | 88.7 | (42.5-163.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.4 | 112.7 | (36.3-263.0) |  |  |  |  |  |  |
| Female | 3 | 1.6 | nc | (nc-nc) |  | Female | 15 | 12.3 | 121.7 | (68.1-200.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 19.9 | 95.3 | (57.3-148.8) |  | Male | 179 | 154.7 | 115.7 | (99.4-133.9) |
| Female | 23 | 23.4 | 98.4 | (62.4-147.7) |  | Female | 189 | 184.5 | 102.4 | (88.4-118.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

186

# Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 29.5 | 44.1 | (23.5-75.4) |  | Male | 16 | 19.1 | 83.8 | (47.9-136.2) |
| Female | 8 | 11.2 | 71.2 | (30.6-140.2) |  | Female | 20 | 15.7 | 127.3 | (77.7-196.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 5.8 | nc | (nc-nc) |  | Male | 7 | 6.1 | 115.1 | (46.1-237.1) |
| Female | 7 | 5.0 | 138.8 | (55.6-286.0) |  | Female | 2 | 5.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 21 | 16.9 | 124.1 | (76.8-189.6) |
| Female | 134 | 125.5 | 106.7 | (89.4-126.4) |  | Female | 22 | 15.5 | 142.1 | (89.0-215.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 14.2 | 77.4 | (38.6-138.5) |
| Female | 2 | 4.2 | nc | (nc-nc) |  | Female | 5 | 6.8 | 73.2 | (23.6-170.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 43 | 31.2 | 137.9 | (99.8-185.8) |  |  |  |  |  |  |
| Female | 40 | 32.0 | 125.2 | (89.4-170.5) |  | Female | 5 | 10.8 | 46.2 | (14.9-107.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 7.5 | 120.0 | (54.8-227.8) |  | Male | 16 | 10.9 | 146.4 | (83.7-237.8) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 13 | 11.7 | 111.2 | (59.1-190.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 79 | 90.2 | 87.6 | (69.3-109.2) |
| Female | 2 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 17.4 | 80.4 | (43.9-134.9) |  | Male | 9 | 7.0 | 129.2 | (59.0-245.3) |
| Female | 6 | 10.1 | 59.3 | (21.7-129.1) |  | Female | 3 | 4.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 4.3 | 161.8 | (64.8-333.5) |  | Male | 3 | 4.6 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 20 | 12.1 | 165.7 | (101.2-255.9) |  | Male | 8 | 8.1 | 99.0 | (42.6-195.0) |
| Female | 9 | 9.1 | 98.6 | (45.0-187.2) |  | Female | 23 | 23.3 | 98.6 | (62.5-147.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 10.4 | 67.3 | (26.9-138.6) |  |  |  |  |  |  |
| Female | 5 | 3.8 | 132.6 | (42.7-309.4) |  | Female | 35 | 28.7 | 122.0 | (85.0-169.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 41 | 51.4 | 79.8 | (57.3-108.3) |  | Male | 361 | 379.9 | 95.0 | (85.5-105.4) |
| Female | 60 | 59.3 | 101.2 | (77.3-130.3) |  | Female | 438 | 421.6 | 103.9 | (94.4-114.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

187

# Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 6.5 | nc | (nc-nc) |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 4 | 2.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 5 | 3.9 | 128.1 | (41.3-299.1) |
| Female | 18 | 25.6 | 70.4 | (41.7-111.3) |  | Female | 4 | 2.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 7.4 | 81.6 | (29.8-177.5) |  |  |  |  |  |  |
| Female | 6 | 5.0 | 120.1 | (43.9-261.4) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 4 | 1.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 18 | 24.0 | 74.9 | (44.4-118.4) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 4.4 | 114.8 | (37.0-268.0) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 7 | 5.2 | 134.4 | (53.8-276.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 8 | 5.9 | 135.2 | (58.2-266.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 11.7 | 68.4 | (29.4-134.7) |  | Male | 64 | 91.1 | 70.2 | (54.1-89.7) |
| Female | 10 | 9.3 | 107.4 | (51.4-197.6) |  | Female | 80 | 76.7 | 104.3 | (82.7-129.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

188

# Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 7.3 | 122.5 | (55.9-232.5) |  | Male | 3 | 4.8 | nc | (nc-nc) |
| Female | 4 | 2.5 | nc | (nc-nc) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 26 | 31.8 | 81.6 | (53.3-119.6) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 3.7 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 7.8 | 102.2 | (44.0-201.4) |  |  |  |  |  |  |
| Female | 6 | 7.3 | 82.6 | (30.2-179.8) |  | Female | 4 | 2.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 18 | 24.0 | 75.0 | (44.4-118.5) |
| Female | 2 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 4.5 | nc | (nc-nc) |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 3 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 6 | 6.0 | 99.9 | (36.5-217.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 0.9 | nc | (nc-nc) |  | Female | 1 | 7.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 13.3 | 120.7 | (69.0-196.1) |  | Male | 90 | 96.7 | 93.1 | (74.9-114.5) |
| Female | 24 | 13.6 | 176.9 | (113.3-263.2) |  | Female | 103 | 101.3 | 101.7 | (83.0-123.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

189

# Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 53 | 49.5 | 107.1 | (80.2-140.0) |  | Male | 24 | 32.3 | 74.3 | (47.6-110.5) |
| Female | 23 | 18.2 | 126.1 | (79.9-189.2) |  | Female | 20 | 26.0 | 76.9 | (46.9-118.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 9.8 | 122.7 | (63.3-214.4) |  | Male | 7 | 10.3 | 68.0 | (27.2-140.1) |
| Female | 10 | 8.4 | 118.4 | (56.7-217.7) |  | Female | 8 | 8.5 | 93.9 | (40.4-185.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 1.8 | nc | (nc-nc) |  | Male | 36 | 28.7 | 125.5 | (87.9-173.8) |
| Female | 186 | 208.7 | 89.1 | (76.8-102.9) |  | Female | 24 | 25.3 | 94.9 | (60.8-141.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 25 | 24.3 | 102.7 | (66.5-151.6) |
| Female | 6 | 6.9 | 86.9 | (31.7-189.0) |  | Female | 9 | 11.2 | 80.0 | (36.5-151.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 48 | 52.6 | 91.2 | (67.2-120.9) |  |  |  |  |  |  |
| Female | 44 | 52.1 | 84.4 | (61.3-113.3) |  | Female | 21 | 18.0 | 116.7 | (72.2-178.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 12.7 | 70.9 | (32.3-134.6) |  | Male | 12 | 18.6 | 64.5 | (33.3-112.7) |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 23 | 18.9 | 121.9 | (77.2-182.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 3.9 | 155.4 | (56.7-338.2) |  | Male | 158 | 152.5 | 103.6 | (88.1-121.1) |
| Female | 0 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 36 | 29.3 | 122.9 | (86.1-170.2) |  | Male | 12 | 11.7 | 102.1 | (52.7-178.4) |
| Female | 20 | 16.6 | 120.1 | (73.4-185.6) |  | Female | 9 | 7.3 | 122.9 | (56.1-233.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 7.4 | 134.5 | (64.4-247.5) |  | Male | 12 | 7.2 | 165.8 | (85.6-289.7) |
| Female | 6 | 2.3 | 258.0 | (94.2-561.7) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 26 | 20.4 | 127.2 | (83.1-186.4) |  | Male | 18 | 13.4 | 134.3 | (79.5-212.2) |
| Female | 15 | 14.8 | 101.0 | (56.5-166.6) |  | Female | 45 | 39.6 | 113.6 | (82.9-152.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 15 | 18.0 | 83.2 | (46.5-137.2) |  |  |  |  |  |  |
| Female | 6 | 6.1 | 98.1 | (35.8-213.5) |  | Female | 50 | 47.3 | 105.6 | (78.4-139.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 101 | 86.7 | 116.6 | (94.9-141.6) |  | Male | 663 | 642.1 | 103.3 | (95.5-111.4) |
| Female | 133 | 96.9 | 137.2 | (114.9-162.6) |  | Female | 733 | 695.0 | 105.5 | (98.0-113.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

190

# Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 37 | 25.4 | 145.9 | (102.7-201.1) |  | Male | 17 | 16.6 | 102.1 | (59.5-163.5) |
| Female | 10 | 9.3 | 107.7 | (51.6-198.1) |  | Female | 15 | 13.2 | 113.8 | (63.7-187.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 5.1 | 136.3 | (54.6-280.8) |  | Male | 5 | 5.4 | 92.5 | (29.8-215.8) |
| Female | 6 | 4.2 | 141.5 | (51.7-308.1) |  | Female | 6 | 4.4 | 137.7 | (50.3-299.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 17 | 14.8 | 115.1 | (67.0-184.2) |
| Female | 109 | 108.3 | 100.6 | (82.6-121.4) |  | Female | 11 | 12.9 | 85.5 | (42.6-153.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 15 | 13.1 | 114.7 | (64.2-189.3) |
| Female | 4 | 3.6 | nc | (nc-nc) |  | Female | 4 | 5.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 26 | 27.3 | 95.1 | (62.1-139.3) |  |  |  |  |  |  |
| Female | 24 | 26.4 | 91.0 | (58.3-135.4) |  | Female | 10 | 9.2 | 109.2 | (52.3-200.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 6.7 | 148.3 | (71.0-272.8) |  | Male | 13 | 9.6 | 134.7 | (71.7-230.4) |
| Female | 3 | 1.8 | nc | (nc-nc) |  | Female | 12 | 9.7 | 124.3 | (64.2-217.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 86 | 84.7 | 101.5 | (81.2-125.4) |
| Female | 2 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 23 | 15.8 | 145.8 | (92.4-218.7) |  | Male | 6 | 6.1 | 98.3 | (35.9-214.0) |
| Female | 6 | 8.5 | 70.2 | (25.6-152.8) |  | Female | 1 | 3.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 4.0 | nc | (nc-nc) |  | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 5 | 1.2 | 412.4 | (132.9-962.5) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 10.5 | 105.1 | (52.4-188.1) |  | Male | 8 | 6.9 | 115.8 | (49.9-228.2) |
| Female | 10 | 7.4 | 134.9 | (64.6-248.2) |  | Female | 25 | 20.2 | 123.8 | (80.1-182.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 9.6 | 125.4 | (64.7-219.1) |  |  |  |  |  |  |
| Female | 6 | 3.1 | 193.9 | (70.8-422.0) |  | Female | 33 | 24.7 | 133.6 | (92.0-187.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 67 | 45.6 | 146.8 | (113.8-186.4) |  | Male | 393 | 338.9 | 116.0 | (104.8-128.0) |
| Female | 80 | 50.1 | 159.7 | (126.6-198.7) |  | Female | 412 | 356.8 | 115.5 | (104.6-127.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

191

# Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 3.1 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 3.6 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 7 | 13.3 | 52.7 | (21.1-108.6) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 8 | 9.7 | 82.9 | (35.7-163.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

192

# Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 11.0 | 154.2 | (89.8-246.9) |  | Male | 8 | 7.4 | 107.5 | (46.3-211.8) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 4 | 4.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 2.3 | 216.6 | (69.8-505.6) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 12 | 6.6 | 181.0 | (93.4-316.2) |
| Female | 38 | 35.5 | 107.0 | (75.7-146.9) |  | Female | 8 | 4.2 | 192.3 | (82.8-378.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 5.9 | 85.1 | (27.4-198.7) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 12.3 | 89.6 | (44.7-160.4) |  |  |  |  |  |  |
| Female | 11 | 8.4 | 130.9 | (65.3-234.3) |  | Female | 0 | 3.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 35 | 36.4 | 96.3 | (67.0-133.9) |
| Female | 2 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 7.0 | nc | (nc-nc) |  | Male | 7 | 2.7 | 261.5 | (104.8-538.9) |
| Female | 4 | 2.8 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.7 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 4.7 | 107.3 | (34.6-250.5) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 12 | 6.4 | 188.8 | (97.4-329.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 15 | 8.2 | 183.6 | (102.7-302.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 19.4 | 87.7 | (51.1-140.5) |  | Male | 151 | 149.1 | 101.3 | (85.8-118.8) |
| Female | 21 | 16.8 | 125.1 | (77.4-191.2) |  | Female | 140 | 116.3 | 120.4 | (101.3-142.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

193

# Milford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 42 | 26.3 | 159.5 | (114.9-215.6) |  | Male | 15 | 17.8 | 84.2 | (47.1-138.9) |
| Female | 17 | 9.8 | 173.0 | (100.7-277.0) |  | Female | 13 | 14.6 | 89.0 | (47.3-152.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 5.5 | 90.1 | (29.0-210.3) |  | Male | 2 | 5.7 | nc | (nc-nc) |
| Female | 5 | 4.8 | 104.8 | (33.8-244.6) |  | Female | 10 | 4.7 | 213.7 | (102.3-393.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 22 | 15.8 | 138.9 | (87.0-210.3) |
| Female | 114 | 116.9 | 97.5 | (80.4-117.1) |  | Female | 18 | 13.9 | 129.2 | (76.6-204.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 18 | 13.6 | 131.9 | (78.1-208.5) |
| Female | 5 | 4.0 | 125.4 | (40.4-292.7) |  | Female | 4 | 6.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 32 | 29.2 | 109.6 | (75.0-154.7) |  |  |  |  |  |  |
| Female | 29 | 28.6 | 101.3 | (67.8-145.4) |  | Female | 9 | 10.0 | 90.0 | (41.1-170.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 6.9 | 115.8 | (49.8-228.1) |  | Male | 10 | 10.0 | 99.8 | (47.8-183.5) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 9 | 10.3 | 87.6 | (40.0-166.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 2.3 | 220.8 | (71.2-515.2) |  | Male | 97 | 82.2 | 118.0 | (95.7-144.0) |
| Female | 1 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 24 | 16.5 | 145.3 | (93.1-216.2) |  | Male | 11 | 6.4 | 172.2 | (85.8-308.1) |
| Female | 12 | 9.2 | 130.7 | (67.5-228.3) |  | Female | 0 | 4.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 4.0 | nc | (nc-nc) |  | Male | 2 | 4.6 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 11.2 | 98.1 | (48.9-175.6) |  | Male | 6 | 8.0 | 75.0 | (27.4-163.4) |
| Female | 9 | 8.3 | 108.5 | (49.5-205.9) |  | Female | 21 | 22.9 | 91.8 | (56.8-140.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 9.8 | 91.8 | (41.9-174.3) |  |  |  |  |  |  |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 22 | 26.7 | 82.4 | (51.6-124.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 50 | 46.4 | 107.8 | (80.0-142.2) |  | Male | 402 | 351.0 | 114.5 | (103.6-126.3) |
| Female | 71 | 51.7 | 137.4 | (107.3-173.3) |  | Female | 412 | 385.5 | 106.9 | (96.8-117.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

194

# Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 16.2 | 135.9 | (85.1-205.8) |  | Male | 10 | 10.3 | 96.6 | (46.3-177.7) |
| Female | 2 | 5.1 | nc | (nc-nc) |  | Female | 8 | 7.3 | 109.8 | (47.3-216.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  | Male | 5 | 3.3 | 151.2 | (48.7-352.9) |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 6 | 2.4 | 249.4 | (91.1-542.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 14 | 9.1 | 153.6 | (83.9-257.7) |
| Female | 64 | 59.6 | 107.4 | (82.7-137.1) |  | Female | 4 | 7.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 7.7 | 129.1 | (61.8-237.4) |
| Female | 4 | 2.0 | nc | (nc-nc) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 16.8 | 71.4 | (36.8-124.7) |  |  |  |  |  |  |
| Female | 12 | 14.6 | 82.2 | (42.4-143.6) |  | Female | 7 | 5.1 | 136.5 | (54.7-281.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 4.1 | 170.3 | (68.2-350.9) |  | Male | 6 | 6.0 | 99.6 | (36.4-216.8) |
| Female | 3 | 1.0 | nc | (nc-nc) |  | Female | 9 | 5.3 | 170.4 | (77.7-323.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 54 | 50.8 | 106.2 | (79.8-138.6) |
| Female | 2 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 9.5 | 105.3 | (50.4-193.6) |  | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 7 | 4.8 | 147.3 | (59.0-303.6) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 2.4 | 250.7 | (91.6-545.7) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 6.4 | 155.5 | (74.4-286.0) |  | Male | 10 | 4.1 | 242.1 | (115.9-445.2) |
| Female | 6 | 4.1 | 145.0 | (52.9-315.6) |  | Female | 13 | 11.1 | 117.0 | (62.3-200.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 5.7 | 87.5 | (28.2-204.2) |  |  |  |  |  |  |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 12 | 13.7 | 87.6 | (45.2-153.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 49 | 28.7 | 170.7 | (126.3-225.7) |  | Male | 253 | 207.7 | 121.8 | (107.3-137.8) |
| Female | 32 | 27.6 | 116.0 | (79.3-163.8) |  | Female | 210 | 196.8 | 106.7 | (92.8-122.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

195

# Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 6.1 | 130.3 | (56.1-256.7) |  | Male | 4 | 4.5 | nc | (nc-nc) |
| Female | 4 | 2.8 | nc | (nc-nc) |  | Female | 6 | 4.4 | 137.6 | (50.2-299.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 4.1 | nc | (nc-nc) |
| Female | 39 | 36.2 | 107.7 | (76.6-147.2) |  | Female | 6 | 4.1 | 146.2 | (53.4-318.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 3.8 | 156.4 | (57.1-340.3) |
| Female | 3 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 7.5 | 106.8 | (46.0-210.4) |  |  |  |  |  |  |
| Female | 8 | 8.3 | 96.0 | (41.3-189.2) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 30 | 22.9 | 131.0 | (88.4-187.0) |
| Female | 3 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 4.5 | 131.9 | (48.2-287.1) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 4 | 2.8 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 4 | 2.4 | nc | (nc-nc) |  | Female | 10 | 7.0 | 142.7 | (68.3-262.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 8 | 8.3 | 95.8 | (41.3-188.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 11.4 | 78.7 | (35.9-149.4) |  | Male | 98 | 91.4 | 107.2 | (87.1-130.7) |
| Female | 23 | 15.7 | 146.5 | (92.8-219.8) |  | Female | 133 | 116.4 | 114.3 | (95.7-135.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

196

# Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 2.1 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 15 | 14.6 | 103.0 | (57.6-170.0) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 3.5 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 11 | 7.9 | 138.4 | (69.0-247.7) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 3 | 0.6 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 0 | 2.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 3.9 | 180.3 | (72.2-371.5) |  | Male | 40 | 32.1 | 124.8 | (89.1-169.9) |
| Female | 9 | 6.4 | 140.6 | (64.2-267.0) |  | Female | 38 | 47.2 | 80.4 | (56.9-110.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

197

# Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 29.1 | 58.5 | (34.0-93.6) |  | Male | 35 | 18.3 | 191.7 | (133.5-266.6) |
| Female | 7 | 10.9 | 64.2 | (25.7-132.3) |  | Female | 24 | 15.0 | 160.4 | (102.7-238.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 5.4 | nc | (nc-nc) |  | Male | 7 | 5.8 | 120.7 | (48.4-248.7) |
| Female | 6 | 4.9 | 121.4 | (44.3-264.2) |  | Female | 10 | 5.0 | 200.0 | (95.7-367.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 21 | 16.1 | 130.1 | (80.5-198.9) |
| Female | 153 | 118.3 | 129.4 | (109.7-151.6) |  | Female | 10 | 14.8 | 67.6 | (32.4-124.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 13.2 | 53.2 | (21.3-109.6) |
| Female | 4 | 4.0 | nc | (nc-nc) |  | Female | 7 | 6.5 | 107.9 | (43.2-222.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 30.1 | 83.2 | (53.8-122.8) |  |  |  |  |  |  |
| Female | 29 | 31.3 | 92.5 | (62.0-132.9) |  | Female | 18 | 10.2 | 176.3 | (104.4-278.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 7.1 | 113.0 | (48.7-222.7) |  | Male | 12 | 10.5 | 113.9 | (58.8-198.9) |
| Female | 4 | 2.1 | nc | (nc-nc) |  | Female | 11 | 11.5 | 96.0 | (47.8-171.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 93 | 82.0 | 113.5 | (91.6-139.0) |
| Female | 4 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 16.1 | 99.2 | (56.7-161.2) |  | Male | 6 | 6.7 | 89.3 | (32.6-194.4) |
| Female | 11 | 9.5 | 115.8 | (57.7-207.1) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 4.0 | nc | (nc-nc) |  | Male | 0 | 3.6 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 11.8 | 119.1 | (65.1-199.9) |  | Male | 6 | 7.1 | 84.2 | (30.8-183.4) |
| Female | 8 | 8.8 | 90.6 | (39.0-178.5) |  | Female | 34 | 21.9 | 155.0 | (107.4-216.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 9.7 | 82.7 | (35.6-162.9) |  |  |  |  |  |  |
| Female | 1 | 3.5 | nc | (nc-nc) |  | Female | 27 | 26.2 | 103.0 | (67.9-149.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 38 | 49.9 | 76.1 | (53.9-104.5) |  | Male | 351 | 359.0 | 97.8 | (87.8-108.6) |
| Female | 48 | 56.2 | 85.5 | (63.0-113.3) |  | Female | 451 | 401.1 | 112.5 | (102.3-123.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

198

# Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 2.2 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

199

# Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 11.0 | 82.1 | (37.5-155.9) |  | Male | 4 | 7.1 | nc | (nc-nc) |
| Female | 1 | 3.4 | nc | (nc-nc) |  | Female | 1 | 5.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 5 | 6.2 | 80.2 | (25.8-187.1) |
| Female | 50 | 44.5 | 112.3 | (83.3-148.0) |  | Female | 7 | 4.9 | 142.0 | (56.9-292.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 5.5 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 11.6 | 94.8 | (47.2-169.6) |  |  |  |  |  |  |
| Female | 5 | 9.7 | 51.8 | (16.7-120.9) |  | Female | 0 | 3.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 33 | 35.3 | 93.5 | (64.3-131.3) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 6.6 | 75.8 | (24.4-176.8) |  | Male | 0 | 2.6 | nc | (nc-nc) |
| Female | 0 | 3.4 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 4.3 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 4 | 8.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 4.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 6 | 10.5 | 57.1 | (20.8-124.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 19.7 | 81.2 | (46.4-131.8) |  | Male | 112 | 142.9 | 78.4 | (64.5-94.3) |
| Female | 14 | 18.6 | 75.3 | (41.1-126.3) |  | Female | 114 | 139.6 | 81.7 | (67.4-98.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

200

# Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 10.3 | 97.4 | (46.6-179.1) |  | Male | 8 | 6.4 | 125.0 | (53.8-246.2) |
| Female | 3 | 4.1 | nc | (nc-nc) |  | Female | 1 | 5.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 1.8 | 275.6 | (88.8-643.2) |  | Male | 4 | 2.1 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 6 | 5.7 | 106.1 | (38.8-231.0) |
| Female | 38 | 44.5 | 85.4 | (60.4-117.3) |  | Female | 3 | 5.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.7 | nc | (nc-nc) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 10.4 | 67.2 | (26.9-138.5) |  |  |  |  |  |  |
| Female | 12 | 11.8 | 101.6 | (52.4-177.5) |  | Female | 6 | 3.9 | 154.8 | (56.5-337.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 2.6 | 311.6 | (134.2-614.0) |  | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 2 | 4.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 17 | 31.1 | 54.7 | (31.8-87.6) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 5.7 | 87.5 | (28.2-204.2) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 4 | 3.6 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 4.0 | 125.7 | (40.5-293.3) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 6 | 3.2 | 184.9 | (67.5-402.6) |  | Female | 3 | 7.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 3.5 | 141.4 | (45.6-330.0) |  |  |  |  |  |  |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 9 | 10.4 | 86.4 | (39.4-164.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 17.9 | 106.2 | (63.9-165.9) |  | Male | 121 | 128.5 | 94.2 | (78.1-112.5) |
| Female | 20 | 21.3 | 93.7 | (57.2-144.7) |  | Female | 124 | 150.8 | 82.2 | (68.4-98.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

201

# Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 3 | 1.1 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 6 | 5.0 | 120.4 | (44.0-262.1) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 5.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  | Male | 13 | 21.3 | 61.0 | (32.4-104.3) |
| Female | 0 | 2.6 | nc | (nc-nc) |  | Female | 11 | 17.1 | 64.2 | (32.0-114.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

202

# Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 4.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 8 | 3.6 | 222.3 | (95.7-438.0) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 16 | 14.4 | 110.8 | (63.3-179.9) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 6 | 14.2 | 42.2 | (15.4-91.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

203

# Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 2 | 4.0 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 3 | 4.4 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

204

# Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 5.4 | 111.5 | (40.7-242.6) |  | Male | 6 | 3.2 | 189.4 | (69.1-412.2) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 7 | 2.7 | 257.9 | (103.3-531.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 19 | 21.5 | 88.4 | (53.2-138.1) |  | Female | 3 | 2.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.3 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 5.1 | 116.8 | (42.7-254.3) |  |  |  |  |  |  |
| Female | 7 | 6.1 | 114.7 | (45.9-236.3) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 24 | 16.0 | 149.7 | (95.9-222.8) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 4 | 4.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 9.3 | 140.0 | (74.5-239.4) |  | Male | 80 | 64.6 | 123.9 | (98.3-154.2) |
| Female | 7 | 10.5 | 66.8 | (26.7-137.6) |  | Female | 67 | 74.3 | 90.2 | (69.9-114.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

205

# Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 11.5 | 69.4 | (29.9-136.7) |  | Male | 15 | 7.7 | 194.8 | (109.0-321.4) |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 16 | 5.1 | 314.3 | (179.6-510.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 7 | 2.5 | 281.2 | (112.6-579.3) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 4 | 6.8 | nc | (nc-nc) |
| Female | 54 | 41.2 | 131.2 | (98.5-171.1) |  | Female | 5 | 4.8 | 103.8 | (33.4-242.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 5.8 | 155.0 | (70.7-294.2) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 4 | 2.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 12.3 | 81.3 | (38.9-149.6) |  |  |  |  |  |  |
| Female | 16 | 9.8 | 163.5 | (93.4-265.6) |  | Female | 4 | 3.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 4 | 0.7 | nc | (nc-nc) |  | Female | 4 | 3.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.0 | nc | (nc-nc) |  | Male | 31 | 36.5 | 85.0 | (57.7-120.6) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 7.1 | nc | (nc-nc) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 0 | 3.3 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 4.8 | 147.2 | (59.0-303.3) |  | Male | 4 | 3.3 | nc | (nc-nc) |
| Female | 5 | 2.9 | 174.5 | (56.2-407.2) |  | Female | 14 | 8.0 | 175.5 | (95.9-294.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 9 | 9.5 | 94.6 | (43.2-179.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 20.8 | 76.8 | (43.9-124.7) |  | Male | 140 | 152.9 | 91.6 | (77.0-108.1) |
| Female | 20 | 18.5 | 108.3 | (66.1-167.3) |  | Female | 176 | 135.0 | 130.4 | (111.9-151.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

206

# Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 28 | 34.3 | 81.7 | (54.3-118.1) |  | Male | 21 | 22.4 | 93.6 | (57.9-143.0) |
| Female | 15 | 13.2 | 113.5 | (63.5-187.2) |  | Female | 19 | 19.5 | 97.7 | (58.8-152.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 6.9 | 72.7 | (23.4-169.7) |  | Male | 5 | 7.1 | 70.1 | (22.6-163.6) |
| Female | 7 | 6.3 | 111.3 | (44.6-229.4) |  | Female | 5 | 6.2 | 80.3 | (25.9-187.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 1.2 | nc | (nc-nc) |  | Male | 18 | 19.9 | 90.3 | (53.5-142.7) |
| Female | 127 | 160.0 | 79.4 | (66.2-94.4) |  | Female | 15 | 18.6 | 80.7 | (45.2-133.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 19 | 16.7 | 113.6 | (68.4-177.4) |
| Female | 3 | 5.4 | nc | (nc-nc) |  | Female | 13 | 8.4 | 155.3 | (82.6-265.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 37 | 36.4 | 101.6 | (71.5-140.1) |  |  |  |  |  |  |
| Female | 48 | 37.9 | 126.5 | (93.3-167.8) |  | Female | 19 | 13.5 | 140.9 | (84.8-220.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 8.7 | 102.9 | (47.0-195.4) |  | Male | 14 | 12.8 | 109.4 | (59.8-183.6) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 12 | 13.6 | 88.3 | (45.6-154.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 102 | 104.6 | 97.5 | (79.5-118.3) |
| Female | 0 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 23 | 20.5 | 112.2 | (71.1-168.3) |  | Male | 9 | 8.1 | 110.7 | (50.5-210.2) |
| Female | 10 | 12.6 | 79.5 | (38.1-146.2) |  | Female | 2 | 5.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 5.1 | 117.9 | (43.1-256.6) |  | Male | 8 | 5.4 | 147.7 | (63.6-291.1) |
| Female | 4 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 14.3 | 105.1 | (58.8-173.3) |  | Male | 12 | 9.5 | 125.7 | (64.9-219.5) |
| Female | 5 | 10.9 | 45.9 | (14.8-107.0) |  | Female | 30 | 30.7 | 97.7 | (65.9-139.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 12.2 | 73.8 | (33.7-140.2) |  |  |  |  |  |  |
| Female | 3 | 4.5 | nc | (nc-nc) |  | Female | 39 | 36.0 | 108.4 | (77.0-148.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 47 | 60.4 | 77.8 | (57.2-103.5) |  | Male | 423 | 444.6 | 95.1 | (86.3-104.6) |
| Female | 62 | 72.0 | 86.1 | (66.0-110.4) |  | Female | 474 | 520.9 | 91.0 | (83.0-99.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

207

# Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 43 | 37.7 | 114.2 | (82.6-153.8) |  | Male | 36 | 23.2 | 155.4 | (108.8-215.2) |
| Female | 16 | 13.4 | 119.6 | (68.3-194.3) |  | Female | 22 | 17.9 | 123.1 | (77.1-186.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 6.6 | 106.5 | (42.6-219.4) |  | Male | 10 | 7.4 | 134.5 | (64.4-247.4) |
| Female | 11 | 5.7 | 191.6 | (95.5-342.8) |  | Female | 6 | 6.1 | 97.7 | (35.7-212.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 25 | 20.5 | 122.2 | (79.1-180.4) |
| Female | 177 | 143.5 | 123.4 | (105.9-142.9) |  | Female | 24 | 17.9 | 134.1 | (85.9-199.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 16.5 | 42.4 | (17.0-87.4) |
| Female | 2 | 4.6 | nc | (nc-nc) |  | Female | 6 | 7.9 | 75.6 | (27.6-164.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 26 | 38.2 | 68.1 | (44.5-99.8) |  |  |  |  |  |  |
| Female | 44 | 38.8 | 113.3 | (82.3-152.1) |  | Female | 11 | 12.4 | 88.9 | (44.3-159.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 9.1 | 99.1 | (45.2-188.2) |  | Male | 7 | 13.6 | 51.6 | (20.7-106.2) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 16 | 14.2 | 112.3 | (64.2-182.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 120 | 105.6 | 113.7 | (94.2-135.9) |
| Female | 2 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 20 | 20.3 | 98.6 | (60.2-152.4) |  | Male | 3 | 8.6 | nc | (nc-nc) |
| Female | 14 | 11.5 | 121.7 | (66.5-204.2) |  | Female | 2 | 5.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 5.2 | nc | (nc-nc) |  | Male | 4 | 4.0 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 14.7 | 88.3 | (47.0-151.1) |  | Male | 12 | 8.6 | 139.7 | (72.1-244.0) |
| Female | 15 | 10.8 | 139.5 | (78.0-230.0) |  | Female | 32 | 25.3 | 126.5 | (86.5-178.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 12.4 | 56.5 | (22.6-116.3) |  |  |  |  |  |  |
| Female | 4 | 4.3 | nc | (nc-nc) |  | Female | 33 | 31.9 | 103.4 | (71.1-145.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 40 | 64.1 | 62.4 | (44.6-84.9) |  | Male | 426 | 457.2 | 93.2 | (84.5-102.5) |
| Female | 38 | 67.9 | 56.0 | (39.6-76.9) |  | Female | 513 | 486.4 | 105.5 | (96.5-115.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

208

# New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 3 | 1.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 4 | 5.9 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 5 | 5.1 | 97.6 | (31.4-227.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

209

# New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 96 | 97.6 | 98.3 | (79.6-120.1) |  | Male | 25 | 62.2 | 40.2 | (26.0-59.3) |
| Female | 25 | 39.4 | 63.5 | (41.1-93.8) |  | Female | 17 | 52.6 | 32.3 | (18.8-51.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 18.6 | 53.7 | (25.7-98.8) |  | Male | 20 | 19.8 | 101.0 | (61.6-155.9) |
| Female | 11 | 17.3 | 63.5 | (31.7-113.7) |  | Female | 15 | 18.0 | 83.5 | (46.7-137.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 46 | 55.3 | 83.2 | (60.9-110.9) |
| Female | 340 | 406.9 | 83.6 | (74.9-92.9) |  | Female | 48 | 52.6 | 91.3 | (67.3-121.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 46 | 45.0 | 102.1 | (74.8-136.2) |
| Female | 17 | 13.2 | 128.9 | (75.0-206.3) |  | Female | 26 | 23.0 | 113.1 | (73.8-165.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 120 | 101.4 | 118.3 | (98.1-141.5) |  |  |  |  |  |  |
| Female | 104 | 113.1 | 92.0 | (75.1-111.4) |  | Female | 30 | 36.0 | 83.4 | (56.3-119.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 24 | 24.1 | 99.5 | (63.7-148.1) |  | Male | 37 | 35.8 | 103.4 | (72.8-142.6) |
| Female | 9 | 7.6 | 118.9 | (54.3-225.8) |  | Female | 50 | 41.7 | 119.9 | (89.0-158.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 8 | 7.6 | 105.4 | (45.4-207.8) |  | Male | 315 | 281.4 | 111.9 | (99.9-125.0) |
| Female | 5 | 6.9 | 72.2 | (23.3-168.5) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 57 | 54.9 | 103.8 | (78.6-134.5) |  | Male | 38 | 22.7 | 167.4 | (118.5-229.8) |
| Female | 40 | 33.3 | 120.1 | (85.8-163.6) |  | Female | 19 | 15.9 | 119.2 | (71.7-186.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 32 | 13.9 | 229.5 | (157.0-324.0) |  | Male | 9 | 14.6 | 61.6 | (28.1-116.9) |
| Female | 6 | 4.6 | 130.3 | (47.6-283.7) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 35 | 39.6 | 88.4 | (61.6-123.0) |  | Male | 20 | 25.0 | 79.9 | (48.8-123.4) |
| Female | 21 | 32.2 | 65.2 | (40.3-99.6) |  | Female | 84 | 74.8 | 112.3 | (89.5-139.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 59 | 33.5 | 176.3 | (134.2-227.5) |  |  |  |  |  |  |
| Female | 15 | 12.8 | 117.2 | (65.5-193.3) |  | Female | 73 | 91.2 | 80.1 | (62.8-100.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 257 | 168.1 | 152.9 | (134.8-172.8) |  | Male | 1349 | 1224.5 | 110.2 | (104.4-116.2) |
| Female | 204 | 198.5 | 102.8 | (89.2-117.9) |  | Female | 1274 | 1410.9 | 90.3 | (85.4-95.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

210

# New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 3 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 4 | 4.9 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 6 | 4.2 | 143.1 | (52.3-311.5) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 20 | 16.0 | 124.7 | (76.1-192.5) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 14 | 16.1 | 87.0 | (47.5-145.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

211

# New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 9 | 9.0 | 99.5 | (45.4-188.9) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 8.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 4.8 | nc | (nc-nc) |  | Male | 18 | 34.2 | 52.6 | (31.2-83.2) |
| Female | 3 | 4.3 | nc | (nc-nc) |  | Female | 22 | 29.3 | 75.0 | (47.0-113.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

212

# New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 3 | 5.4 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 1.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 5.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 14 | 19.0 | 73.6 | (40.2-123.5) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 15 | 17.8 | 84.1 | (47.0-138.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

213